Document is current
Any future updates will be listed below
-
Authors
Kajdácsi, Erika https://orcid.org/0000-0003-0739-2193
Veszeli, Nóra https://orcid.org/0000-0002-7647-2173
Mező, Blanka https://orcid.org/0000-0002-9750-1682
Jandrasics, Zsófia
Kőhalmi, Kinga Viktória https://orcid.org/0000-0002-7381-6866
Ferrara, Anne Lise https://orcid.org/0000-0003-1839-8873
Cervenak, László https://orcid.org/0000-0003-0166-8697
Varga, Lilian https://orcid.org/0000-0002-5484-364X
Farkas, Henriette
-
Funding
Funding for this research was provided by:
Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (K124557)
Semmelweis University
- License Information
-
More Information
Article History
Accepted: 26 January 2021
First Online: 19 February 2021
Declarations
:
: The study protocol was approved by the institutional review board of Semmelweis University of Budapest, and informed consent was obtained from all the participants in accordance with the Declaration of Helsinki.
: KVK received honoraria and travel grants from CSL Behring and Shire and has participated in clinical trials of BioCryst, CSL Behring, Pharming, and Shire. LV received travel grants from CSL Behring and Shire Human Genetic Therapies Inc. HF received honoraria and travel grants from CSL Behring, Shire/Takeda, Swedish Orphan Biovitrum, Octapharma, Kalvista and Pharming; and/or served as a consultant for these companies and has participated in clinical trials/registries for BioCryst, CSL Behring, Pharming, and Shire. Other authors have declared no conflict of interest.
